Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Mantle Cell Lymphoma
Related studies linked through entity extraction aliases.
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Imexon for Relapsed Follicular and Aggressive Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
AMG 319 Lymphoid Malignancy FIH
- Status
- COMPLETED
- Phase
- PHASE1
Nonmyeloablative Allogeneic Transplant
- Status
- COMPLETED
- Phase
- NA
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
- Status
- COMPLETED
- Phase
- PHASE2
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE3
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
- Status
- COMPLETED
- Phase
- PHASE3